Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00992238 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Padagis.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00992238: Completed Phase 1 study, sponsored by Padagis.
NCT00992238 is a Phase 1 study that has completed, run by Padagis. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00992238, a Phase 1 study, has completed, sponsored by Padagis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the relative bioavailability of Flavoxate Hydrochloride tablets 100mg manufactured by Paddock Laboratories, Inc., with that of Urispas® tablets 100mg by SmithKline Beecham Pharmaceuticals under fasting conditions.
Interventions
- DRUG Flavoxate Hydrochloride Tablets, 100mg
- DRUG Urispas® Tablets, 100mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Phase | Phase 1 |
What the finished NCT00992238 record still lists
NCT00992238 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 2 interventions - of which Flavoxate Hydrochloride Tablets, 100mg is the first listed.
NCT00992238 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00992238 about?
NCT00992238 is a clinical study titled "A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions". The purpose of this study is to compare the relative bioavailability of Flavoxate Hydrochloride tablets 100mg manufactured by Paddock Laboratories, Inc., with that of Urispas® tablets 100mg by SmithKline Beecham Pharmaceuticals under fasting conditions.
What is the current status of trial NCT00992238?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants.
What interventions are being tested in trial NCT00992238?
The interventions under investigation include: Flavoxate Hydrochloride Tablets, 100mg (DRUG), Urispas® Tablets, 100mg (DRUG).
Who is sponsoring clinical trial NCT00992238?
This trial is sponsored by Padagis, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00992238's enrollment target sits among peer trials
48 1025th of 2000 higher than 948 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention